Baudax Bio Inc (NASDAQ:BXRX) traded with an addition of $0.24 to $0.54 on Thursday, an upside of 80.50 percent. An average of 21,353,193 shares of common stock have been traded in the last five days. There was a gain of $0.2945 in the past week, and it reached a new high 3 times over the past 12 months. The last 20 days have seen an average of 5,411,878 shares traded, while the 50-day average volume stands at 2,237,141.
BXRX stock has increased by 21.20% in the last month. The company shares reached their 1-month lowest point of $0.3000 on 09/27/23. With the stock rallying to its 52-week high on 01/24/23, shares of the company touched a low of $0.30 and a high of $12.24 in 52 weeks. It has reached a new high 2 times so far this year and lost -82.97% or -$2.5405 in price. In spite of this, the price is down -95.58% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Valuation Metrics
Baudax Bio Inc (BXRX) has a trailing price-to-earnings (P/E) ratio of N/A for the broader industry. The stock’s beta is 2.07. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.04.
Financial Health
The quick ratio of Baudax Bio Inc for the three months ended June 29 was 0.09, and the current ratio was 0.09, indicating that the company is not able to meet its debt obligations. Baudax Bio Inc’s EBITDA margin for the year ending June 29 is -2646.26%, while its operating margin for the same period stands at -4099.45%. Its gross profit as reported stood at -$5.74 million compared to revenue of $1.27 million.
Earnings Surprise
The company posted a net income of -$7.38 million in the quarter, while revenues of $11.4 million were shrunk -2.03%. The analyst consensus anticipated Baudax Bio Inc’s latest quarter earnings to come in at -$2.04 per share, but it turned out to be -$1.52, a 25.50% surprise. For the quarter, EBITDA amounted to -$7.04 million. Shareholders own equity worth $6.97 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Baudax Bio Inc (BXRX) price momentum. RSI 9-day as of the close on 27 September was 82.06%, suggesting the stock is Overbought, with historical volatility in this time frame at 390.42%.
As of today, BXRX’s price is $0.3888 +85.36% or $0.2945 from its 5-day moving average. BXRX is currently trading +44.03% higher than its 20-day SMA and -15.84% lower than its 100-day SMA. However, the stock’s current price level is -30.49% below the SMA50 and -87.70% below the SMA200.
The stochastic %K and %D were 34.40% and 23.85%, respectively, and the average true range (ATR) was 0.0782. With the 14-day stochastic at 70.73% and the average true range at 0.0636, the RSI (14) stands at 73.34%. The stock has reached 0.0463 on the 9-day MACD Oscillator while the 14-day reading was at 0.0477.
Analyst Ratings
JMP Securities launched coverage on Baudax Bio Inc (NASDAQ: BXRX) in its analyst report released on May 15, 2020. The firm assigned the stock a Mkt outperform rating. The consensus rating for Baudax Bio Inc (BXRX) among analysts is Hold. According to current brokerage recommendations, 0 brokerage firms advise that investors sell BXRX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 0 others rate it as a “buy”.
